Abstract:Glucagon-like peptide-2 (GLP-2), an intestinotrophic hormone, has drawn considerable attention worldwide due to its potential to promote intestinal development. We investigated the effects and mechanisms of GLP-2 against lipopolysaccharide (LPS)-induced intestinal inflammation and injury both in vitro and in vivo. Forty healthy piglets weaned at the age of 28 days with similar body weight (BW) were assigned to four in vivo treatments with ten piglets each: (i) nonchallenged control; (ii) LPS-challenged control; (iii) LPS + low dose GLP-2; and (iv) LPS + high dose GLP-2. Piglets were subcutaneously injected with phosphate-buffered saline supplemented with GLP-2 at doses of 0, 0, 2, and 10 nmol/kg BW per day for seven consecutive days. The piglets were challenged with an intraperitoneal injection with 100 mu g/kg LPS on day 14 to induce intestinal damage. After that, the gene and protein expression levels of representative tight junction proteins and myosin light-chain kinase (MLCK)/phosphorylated myosin light chain (pMLC), as well as proinflammatory cytokine levels were determined using quantitative reverse transcription polymerase chain reaction, western blot, and enzyme-linked immunosorbent assay methods. A high dose of GLP-2 pretreatment increased intestinal permeability by downregulating and redistributing tight junction proteins (p < .05), for example, zona occluden-1 (ZO-1) and occludin. GLP-2 decreased the transcription of proinflammatory cytokines genes including interleukin-1 beta (IL-1 beta), IL-6, IL-8, and tumor necrosis factor-alpha in small intestines (p < .05). GLP-2 prevented the LPS-induced increase in the expression of MLCK dose-dependently and the increase in pMLC levels in the duodenum, jejunum, and ileum. To assess further the protective effect of GLP-2 on LPS-induced intestinal barrier injury after weaning and its possible mechanism, an in vitro intestinal epithelial barrier model was established with IPEC-J2 monolayers and treated with 100 mu g/ml LPS with or without 1 x 10(-8) mol/L GLP-2 pretreatment. The in vitro analysis included control, LPS, and GLP-2 + LPS treatments. GLP-2 treatment alleviated the destructive effect of LPS on barrier permeability by restoring the expression and ultrastructure of ZO-1 and occludin (p < .05). In addition, GLP-2 reversed the LPS-induced MLCK hyperexpression and pMLC hyperphosphorylation (p < .05). Taken together, our findings revealed a mechanism by which GLP-2 alleviated LPS-challenged intestinal barrier injury and inflammation in weaned piglets and IPEC-J2 cells via the MLCK/pMLC signaling pathway.

Glucagon-Like Peptide-2 Improve Intestinal Mucosal Barrier Function in Aged Rats

Effect of Aging and Glucagon-like Peptide 2 on Intestinal Microbiota in SD Rats.

Glucagon-Like Peptide-2 Ameliorates Age-Associated Bone Loss and Gut Barrier Dysfunction in Senescence-Accelerated Mouse Prone 6 Mice

Effect of ageing on intestinal barrier function in D-galactose-induced rat aging model

Parishin from Gastrodia Elata Ameliorates Aging Phenotype in Mice in a Gut Microbiota-Related Manner

Glucagon-Like Peptide-2 Modulates Enteric Paneth Cells Immune Response and Alleviates Gut Inflammation During Intravenous Fluid Infusion in Mice With a Central Catheter

GLP-2 ameliorates D-galactose induced muscle aging by IGF-1/Pi3k/Akt/FoxO3a signaling pathway in C2C12 cells and mice

Glucagon‐like Peptide 2 Attenuates Intestinal Mucosal Barrier Injury Through the MLCK/pMLC Signaling Pathway in a Piglet Model

Glp-2 Prevents Intestinal Mucosal Atrophy And Improves Tissue Antioxidant Capacity In A Mouse Model Of Total Parenteral Nutrition

Colonic L-cell impairment in aged subjects with type 2 diabetes leads to diminished GLP-1 production

Effects of Glucagon-Like Peptide 2 on the Adaptation of Residual Small Bowel in a Rat Model of Short Bowel Syndrome

Glucagonlike peptide 2 protects intestinal barrier in severe acute pancreatitis through regulating intestinal epithelial cell proliferation and apoptosis.

Effect of intraintestinal short chain fatty acids on gut barrier function in aging mice

Effects of glucagon-like peptide-2 on the recovery of structure and function of small intestinal following orthotopic transplantation

Polysaccharide ORP-1 isolated from Oudemansiella raphanipes ameliorates age-associated intestinal epithelial barrier dysfunction in Caco-2 cells monolayer

Alteration of glucagon-like peptide-2 (GLP-2) on proliferation of intestinal mucosa in rats following small bowel resection and its time-dependent pattern

Ganoderma Lucidum Polysaccharides Ameliorates D-galactose-induced Aging Salivary Secretion Disorders by Upregulating the Rhythm and Aquaporins.

Astragalus membranaceus Polysaccharide Regulates Small Intestinal Microbes and Activates IL-22 Signal Pathway to Promote Intestinal Stem Cell Regeneration in Aging Mice

Glucagon-like Peptide-2 Improves Intestinal Immune Function and Diminishes Bacterial Translocation in a Mouse Model of Parenteral Nutrition

[Effect of Glucagon-Like Peptide 2 on the Intestinal Mucosal Immunity and Correlative Cytokines in Mice with Gut Ischemia/reperfusion Injury].

Age-Related Mucus Barrier Dysfunction in Mice Is Related to the Changes in Muc2 Mucin in the Colon